dr. al-sawaf on testing for ckt in cll
Published 4 years ago • 824 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
0:56
dr. al-sawaf on continual mrd assessment after venetoclax/obinutuzumab in cll
-
1:16
dr. al-sawaf on fixed-duration versus continuous treatment in cll
-
1:46
dr. al-sawaf on updated pfs data with venetoclax plus obinutuzumab in cll
-
1:42
dr. al-sawaf on new safety signals with venetoclax/obinutuzumab in the cll14 trial
-
5:09
othman al-sawaf, md, on the role of mrd in the management of cll as a result of data from ash 2020
-
1:06
treatment options for cll patients with poor prognostic markers
-
2:27
othman al-sawaf, md, regarding the standard of care for first-line treatment of newly diagnosed cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:54
dr. fakhri on selecting the optimal treatment in cll
-
4:42
advances in frontline therapy for cll
-
7:59
othman al sawaf, asco20: results of the phase iii cll14 trial for chronic lymphocytic leukaemia
-
0:45
dr. wierda discusses watchful waiting in cll
-
5:49
initial work-up for chronic lymphocytic leukemia
-
1:12
dr. mato on immunotherapy options in cll
-
1:29
dr. james on update of ibrutinib for chronic lymphocytic leukemia
-
7:04
understanding mrd testing in cll
-
3:46
severe infections impact prognosis for cll patients receiving cit
-
1:13
dr. wierda discusses the need for newer therapies in cll
-
3:26
cll: value of mrd testing